Celldex Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference
February 22, 2021 08:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the Company will participate in a fireside chat at the 10th Annual SVB Leerink Global...
Celldex Appoints Freddy A. Jimenez, Esq. as Senior Vice President and General Counsel
January 04, 2021 08:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the promotion of Freddy A. Jimenez, Esq. to Senior Vice President and General Counsel,...
Celldex Doses First Patient in Phase 1b Study of CDX-0159 in Chronic Inducible Urticaria
December 09, 2020 08:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that the first patient has been dosed in its open label clinical trial in cold contact...
Celldex Therapeutics to Present at 3rd Annual Evercore ISI HealthCONx Conference
November 30, 2020 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in a fireside chat at the 3rd Annual Evercore ISI...
Celldex Presents Data from Oncology Portfolio at SITC 2020
November 09, 2020 08:01 ET
|
Celldex Therapeutics, Inc.
-- Agonist anti-CD40 mAb CDX-1140 demonstrates best-in-class potential; additional expansion cohorts initiated----Axl and CDX-527 programs highlighted-- HAMPTON, N.J., Nov. 09, 2020 (GLOBE...
Celldex Provides Corporate Update and Reports Third Quarter 2020 Results
November 05, 2020 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2020. “In the...
Celldex Therapeutics Initiates Phase 1b Study of CDX-0159 in Chronic Spontaneous Urticaria
October 13, 2020 08:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened and the first patient has been dosed in its randomized,...
Celldex Therapeutics to Present at Upcoming Healthcare Conferences
September 10, 2020 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in Fireside Chats at the Cantor Virtual Global Healthcare...
Celldex Therapeutics Initiates Phase 1 Study of New Bispecific Product Candidate CDX-527 in Solid Tumors
August 24, 2020 08:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened in its open-label, Phase 1 study of CDX-527 in patients with...
Celldex Provides Corporate Update and Reports Second Quarter 2020 Results
August 06, 2020 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2020. The Company...